RecruitingObese or Overweight Healthy VolunteersType 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Eligible age
18–75 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
Sponsor: Alnylam Pharmaceuticals
You may qualify if…
- ✓ Part A:
- ✓ Has a body mass index (BMI) of ≥27 kg/m\^2 and \<40 kg/m\^2
- ✓ Part B:
- ✓ Is an adult patient with a confirmed diagnosis of T2DM
- ✓ Has a hemoglobin A1c (HbA1c) ≥7% to \<10.5%
- ✓ Has a BMI of ≥25 kg/m\^2 and \<45 kg/m\^2
- ✓ Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i)
You may not qualify if…
- ✕ Part A:
- ✕ Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
- ✕ Part B:
- ✕ Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i
- ✕ Note: other protocol defined inclusion/exclusion criteria apply
Where it's recruiting
California
Montclair
District of Columbia
Washington D.C.
Florida
Miami
New Jersey
Marlton
North Carolina
Monroe
Texas
Dallas
Source: ClinicalTrials.gov · NCT06845202 · last updated 2026-06-12